PDZ Domain Binding Selectivity Is Optimized Across the Mouse Proteome

PDZ domains have long been thought to cluster into discrete functional classes defined by their peptide-binding preferences. We used protein microarrays and quantitative fluorescence polarization to characterize the binding selectivity of 157 mouse PDZ domains with respect to 217 genome-encoded pept...

Full description

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 317; no. 5836; pp. 364 - 369
Main Authors Stiffler, Michael A, Chen, Jiunn R, Grantcharova, Viara P, Lei, Ying, Fuchs, Daniel, Allen, John E, Zaslavskaia, Lioudmila A, MacBeath, Gavin
Format Journal Article
LanguageEnglish
Published Washington, DC American Association for the Advancement of Science 20.07.2007
The American Association for the Advancement of Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:PDZ domains have long been thought to cluster into discrete functional classes defined by their peptide-binding preferences. We used protein microarrays and quantitative fluorescence polarization to characterize the binding selectivity of 157 mouse PDZ domains with respect to 217 genome-encoded peptides. We then trained a multidomain selectivity model to predict PDZ domain-peptide interactions across the mouse proteome with an accuracy that exceeds many large-scale, experimental investigations of protein-protein interactions. Contrary to the current paradigm, PDZ domains do not fall into discrete classes; instead, they are evenly distributed throughout selectivity space, which suggests that they have been optimized across the proteome to minimize cross-reactivity. We predict that focusing on families of interaction domains, which facilitates the integration of experimentation and modeling, will play an increasingly important role in future investigations of protein function.
Bibliography:http://www.scienceonline.org/
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
Present address: Merrimack Pharmaceuticals, 1 Kendall Square, Building 700, Cambridge, MA 02139, USA.
These authors contributed equally to this work.
Present address: Tepnel Lifecodes Corporation, 550 West Avenue, Stamford, CT 06902, USA.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.1144592